Creo Medical Group (LON:CREO) Announces Quarterly Earnings Results

Creo Medical Group (LON:CREO) posted its quarterly earnings results on Wednesday. The company reported GBX (2) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%.

Creo Medical Group Stock Performance

LON:CREO traded down GBX 1.48 during trading hours on Wednesday, reaching GBX 10.40. The company had a trading volume of 7,994,368 shares, compared to its average volume of 783,030. Creo Medical Group has a 1-year low of GBX 9.52 and a 1-year high of GBX 18.50. The firm has a market cap of £50.52 million, a PE ratio of 10.40 and a beta of 1.56. The business’s 50 day moving average price is GBX 12.77 and its 200-day moving average price is GBX 12.87. The company has a debt-to-equity ratio of 8.20, a current ratio of 3.22 and a quick ratio of 2.19.

Wall Street Analysts Forecast Growth

Separately, Shore Capital Group reiterated a “house stock” rating and issued a GBX 40 price objective on shares of Creo Medical Group in a research note on Thursday, July 23rd.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.